{
    "id": 4948,
    "name": "gallbladder carcinoma",
    "source": "DOID",
    "definition": "A gallbladder cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. [url:https\\://www.mayoclinic.org/diseases-conditions/gallbladder-cancer/symptoms-causes/syc-20353370]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:4948",
    "evidence": [
        {
            "id": 16212,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapitinib (AZD8931) reduced downstream p-ERK and p-AKT signaling and cell viability in gallbladder carcinoma cell lines expressing ERBB2 (HER2) S310F and CD274 (PD-L1) in culture (PMID: 29954840).",
            "molecularProfile": {
                "id": 31585,
                "profileName": "CD274 pos ERBB2 S310F"
            },
            "therapy": {
                "id": 910,
                "therapyName": "Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4948,
                "name": "gallbladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14332,
                    "pubMedId": 29954840,
                    "title": "Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29954840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16213,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapitinib (AZD8931) reduced downstream p-ERK and p-AKT signaling and cell viability in gallbladder carcinoma cell lines expressing ERBB3 (HER3) D581N and CD274 (PD-L1) in culture (PMID: 29954840).",
            "molecularProfile": {
                "id": 31588,
                "profileName": "CD274 pos ERBB3 D581N"
            },
            "therapy": {
                "id": 910,
                "therapyName": "Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4948,
                "name": "gallbladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14332,
                    "pubMedId": 29954840,
                    "title": "Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29954840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16214,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapitinib (AZD8931) reduced downstream p-ERK and p-AKT signaling and cell viability in gallbladder carcinoma cell lines expressing ERBB3 (HER3) P590H and CD274 (PD-L1) in culture (PMID: 29954840).",
            "molecularProfile": {
                "id": 31589,
                "profileName": "CD274 pos ERBB3 P590H"
            },
            "therapy": {
                "id": 910,
                "therapyName": "Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4948,
                "name": "gallbladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14332,
                    "pubMedId": 29954840,
                    "title": "Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29954840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16215,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapitinib (AZD8931) treatment of gallbladder carcinoma cell lines expressing ERBB2 (HER2) S310Y and CD274 (PD-L1) resulted in reduced downstream signaling, decreased viability in a co-culture assay with peripheral blood mononuclear cells, and reduced tumor growth and Cd274 (PD-L1) expression in a cell line xenograft mouse model (PMID: 29954840).",
            "molecularProfile": {
                "id": 31586,
                "profileName": "CD274 pos ERBB2 S310Y"
            },
            "therapy": {
                "id": 910,
                "therapyName": "Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4948,
                "name": "gallbladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14332,
                    "pubMedId": 29954840,
                    "title": "Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29954840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16216,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapitinib (AZD8931) treatment of gallbladder carcinoma cell lines expressing ERBB3 (HER3) V104L and CD274 (PD-L1) resulted in reduced downstream signaling, decreased viability in a co-culture assay with peripheral blood mononuclear cells, and reduced tumor growth and Cd274 (PD-L1) expression in a cell line xenograft mouse model (PMID: 29954840).",
            "molecularProfile": {
                "id": 31587,
                "profileName": "CD274 pos ERBB3 V104L"
            },
            "therapy": {
                "id": 910,
                "therapyName": "Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4948,
                "name": "gallbladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14332,
                    "pubMedId": 29954840,
                    "title": "Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29954840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16217,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tecentriq (atezolizumab) treatment of a gallbladder carcinoma cell line expressing ERBB3 (HER3) V104L and CD274 (PD-L1) resulted in reduced downstream signaling, decreased viability in a co-culture assay with peripheral blood mononuclear cells, and reduced tumor growth in a cell line xenograft mouse model (PMID: 29954840).",
            "molecularProfile": {
                "id": 31587,
                "profileName": "CD274 pos ERBB3 V104L"
            },
            "therapy": {
                "id": 1201,
                "therapyName": "Atezolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 4948,
                "name": "gallbladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14332,
                    "pubMedId": 29954840,
                    "title": "Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29954840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16218,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined Sapitinib (AZD8931) and Tecentriq (atezolizumab) treatment decreased viability of a gallbladder carcinoma cell line expressing ERBB2 (HER2) S310Y and CD274 (PD-L1) in a co-culture assay with peripheral blood mononuclear cells, and reduced tumor growth and increased apoptosis in a cell line xenograft mouse model relative to either therapy alone (PMID: 29954840).",
            "molecularProfile": {
                "id": 31586,
                "profileName": "CD274 pos ERBB2 S310Y"
            },
            "therapy": {
                "id": 7941,
                "therapyName": "Atezolizumab + Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4948,
                "name": "gallbladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14332,
                    "pubMedId": 29954840,
                    "title": "Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29954840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16219,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined Sapitinib (AZD8931) and Tecentriq (atezolizumab) treatment decreased viability of a gallbladder carcinoma cell line expressing ERBB3 (HER3) V104L and CD274 (PD-L1) in a co-culture assay with peripheral blood mononuclear cells, and reduced tumor growth and increase apoptosis in a cell line xenograft mouse model relative to either therapy alone (PMID: 29954840).",
            "molecularProfile": {
                "id": 31587,
                "profileName": "CD274 pos ERBB3 V104L"
            },
            "therapy": {
                "id": 7941,
                "therapyName": "Atezolizumab + Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4948,
                "name": "gallbladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14332,
                    "pubMedId": 29954840,
                    "title": "Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29954840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16313,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tecentriq (atezolizumab) treatment of a gallbladder carcinoma cell line expressing ERBB2 (HER2) S310Y and CD274 (PD-L1) resulted in decreased viability in a co-culture assay with peripheral blood mononuclear cells, and reduced tumor growth in a cell line xenograft mouse model (PMID: 29954840).",
            "molecularProfile": {
                "id": 31586,
                "profileName": "CD274 pos ERBB2 S310Y"
            },
            "therapy": {
                "id": 1201,
                "therapyName": "Atezolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 4948,
                "name": "gallbladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14332,
                    "pubMedId": 29954840,
                    "title": "Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29954840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01174121",
            "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02042443",
            "title": "Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2278,
                    "therapyName": "Fluorouracil + Leucovorin",
                    "synonyms": null
                },
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02115542",
            "title": "Single Agent Regorafenib in Refractory Advanced Biliary Cancers",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02151084",
            "title": "A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2222,
                    "therapyName": "Cisplatin + Gemcitabine + Selumetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02631590",
            "title": "Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3315,
                    "therapyName": "Cisplatin + Copanlisib + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02829918",
            "title": "Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04003896",
            "title": "A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma Who Failed Prior First Line Therapy",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04068194",
            "title": "Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                },
                {
                    "id": 7558,
                    "therapyName": "Avelumab + MSC2490484A",
                    "synonyms": null
                }
            ]
        }
    ]
}